Boehringer Ingelheim advances IL-11 ... • BI 765423 has been developed to target IL-11, a key driver of fibrosis • The potential first-in-class inhibitor is an acquired asset from Enleofen with ...

Boehringer Ingelheim begins phase IIa trial of BI 765423, a novel monoclonal antibody targeting IL-11, in patients with idiopathic pulmonary fibrosis: Ingelheim, Germany Thursday, ...

Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis New study will investigate potential of BI 765423 to improve lung function for patients with ...

Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis New study will investigate potential of BI 765423 to improve lung function for patients ...

Not intended for US and UK audiences ...

Introduction: Several studies have reported an up-regulation of interleukin (IL)-36 in the serum of patients with systemic lupus erythematosus (SLE). Here, we sought to define the mechanisms whereby ...

When inflammation in the body goes unchecked, it can cause fibrosis, or tissue scarring that may lead to organ dysfunction or ...

After a couple snowy buy fairly seasonal days, a one-two punch of arctic cold fronts brings a return of weather we haven't felt since December's frigid cold Wisconsin Assembly passes bill to eliminate ...

An 11-year-old girl was killed in a shooting at a West End playground on New Year's Day, according to Cincinnati police. Police responded around 6:42 p.m. to Laurel Playground at the intersection of ...

The first patient received dosing at Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine.

SHANGHAI, Dec. 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of its ...